Business Wire

SEOUL-SEMICONDUCTOR

29.10.2021 09:20:08 CEST | Business Wire | Press release

Share
In a Clinical Trial, Daytime Exposure to Short-Wavelength Enriched Light With Daylight-like Spectrum Improves Learning and Memory Function

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that following Seoul National University in Korea and Basel University in Europe, a research team found that exposure to short-wavelength enriched light with daylight-like spectrum improves key components of learning such as working memory, cognitive processing speed, and testing accuracy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211029005138/en/

The clinical trial began in 2019, conducted by the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, and included college-aged adults. The results from the study clearly showed the effectiveness of improving procedural learning.

Shadab Rahman, PhD MPH, a researcher in the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital and Assistant Professor of Medicine at Harvard Medical School, led the study along with Leilah Grant, PhD, Melissa St. Hilaire, PhD, Steven Lockley, PhD, and other researchers at the Brigham. Dr. Rahman said, “Even if the color temperature and brightness are the same, light with different spectra may affect non-visual responses to light exposure, including those of circadian rhythms and cognition, differently. In this experiment, we found improvement in working memory, cognitive processing speed, procedural learning, and testing accuracy with young adults under daylight-like light spectrum lighting compared to conventional-LED spectrum lighting. This is an important result that can inform lighting choices for indoor use to enhance students’ learning and memory function.”

The daylight-like spectrum lighting used in the study was provided by Seoul Semiconductor Co., Ltd., makers of SunLike. SunLike is an optical semiconductor technology that reproduces the natural sunlight spectrum curve, that is, the intensity of light for each wavelength of red, orange, yellow, green, blue, and purple. This new concept of LED light source embodies almost the same characteristics of natural light and is optimized for human 24-hour circadian rhythm accordingly.

There has been an increase in research activity on the relationship between light and human bio-function, including a recent scientific study focusing on the effects of light spectrum on sleep quality, visual comfort, well-being and daytime alertness conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland, entitled: ‘Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,’ published in the Journal of Lighting and Research Technology on March 24, 2019. In addition, in an experiment at Seoul National University College of Medicine in July 2018, it was demonstrated that vitality and alertness were increased when SunLike LED lighting was used.

“As the saying goes, ‘Mother Nature is great’, the human body has a 24-hour circadian clock that has evolved to set its time by tracking the daily cycle of sunlight. SunLike is a technology that reproduces all wavelengths of visible light as closely as possible to sunlight. We've been working on R&D over the past 30 years to optimize this technology to provide plants, animals and humans access to light that is closest to sunlight to promote healthy circadian rhythms and sleep, which can also help children and students to study effectively and maintain good health”, said Chung-hoon Lee, CEO of Seoul Semiconductor.

Seoul Semiconductor and Toshiba Materials were jointly involved in the development and release of SunLike in 2017, which has needed investment to further expand stable production and sales. As a result of continuous consultations between the two companies over the past two years to improve the speed of decision and operational efficiency for the SunLike business, Seoul Semiconductor has acquired all technologies, patents, trademarks, etc. related to SunLike, the light most similar to sunlight. Key workers from Toshiba Materials also joined Seoul Semiconductor, and they began efforts to expand sales from September.

About Seoul Semiconductor

Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en .

Link:

ClickThru

Social Media:

https://www.facebook.com/seoulsemiconductorglobal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye